Lunai Bioworks Announces 1-for-8 Reverse Stock Split

Written by Emily J. Thompson, Senior Investment Analyst

Updated: 1 hour ago

0mins

Should l Buy LNAI?

Lunai Bioworks announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-8. The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on May 22, and the Company's Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on May 22, 2026, under the existing trading symbol "LNAI." The Company's Common Stock will trade under a new CUSIP number, 29350E302 following the effectiveness of the Reverse Stock Split.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy LNAI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on LNAI

About LNAI

Lunai Bioworks, Inc is focused on AI-powered biodefense, drug discovery and advanced diagnostics. It is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Lunai Bioworks Announces Reverse Stock Split

1 hour agoNewsfilter

Reverse Stock Split Announcement: Lunai Bioworks has announced a 1-for-8 reverse stock split effective May 22, 2026, aimed at increasing the market price per share to comply with Nasdaq listing rules, reducing outstanding shares from approximately 36.27 million to about 4.53 million.
Shareholder Approval: At a special meeting on May 8, 2026, shareholders approved the board's proposal to allow a reverse stock split within a range of 1-for-3 to 1-for-30, with the final ratio set at 1-for-8, indicating strong support for the company's strategic direction.
Trading Adjustments: Following the reverse stock split, the company's common stock will trade under a new CUSIP number 29350E302, with all holdings automatically adjusted, ensuring shareholders holding shares electronically do not need to take additional action to receive their post-split shares.
Market Compliance: This reverse stock split is intended to assist the company in regaining compliance with Nasdaq requirements, as a previous 1-for-10 reverse stock split on September 30, 2025, failed to effectively boost the stock price, highlighting ongoing challenges in the market.